



➔ **Cover Image**

Bimodal gaussian distribution of PET signal in the Harvard Aging Brain Study. Histograms of the baseline PET data in each sample are plotted and fitted to a bimodal gaussian distribution using Gaussian Mixture Model. Stylized by Kaitlyn Aman Ramm, Digital Multimedia/Graphics Coordinator. See page 157

Editorials

- 139 **Optic Nerve in Multiple Sclerosis Diagnostic Criteria: An Eye to the Eyes?**
W.J. Brownlee and S. Galetta
- 141 **Ibudilast: A Paradigm Shift for Progressive Multiple Sclerosis?**
M.P. Sormani, C. Tur, and F. Barkhof
- 143 **Cancer and Stroke: A Relationship Thicker Than Blood**
R. Hurford and R.E. Strowd III

Articles: Short Format

Full articles at [Neurology.org/N](https://www.neurology.org/N)

- 145 **Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials**
A. Vidal-Jordana, A. Rovira, G. Arrambide, S. Otero-Romero, J. Río, M. Comabella, C. Nos, J. Castelló, I. Galan, S. Cabello, D. Moncho, K. Rahnama, V. Thonon, B. Rodríguez-Acevedo, A. Zabalza, L. Midaglia, C. Auger, J. Sastre-Garriga, X. Montalban, and M. Tintoré
➔ Editorial, p. 139 [Open Access Article](#)
- 146 **Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study**
R.T. Naismith, R.A. Bermel, C.S. Coffey, A.D. Goodman, J. Fedler, M. Kearney, E.C. Klawiter, K. Nakamura, S. Narayanan, C. Goebel, J. Yankey, E. Klingner, and R.J. Fox, on behalf of the SPRINT-MS investigators
➔ Editorial, p. 141 ➔ [Class of Evidence](#)
- 147 **Cancer Incidence and Mortality Rates in Multiple Sclerosis: A Matched Cohort Study**
R.A. Marrie, C. Maxwell, A. Mahar, O. Ekuma, C. McClintock, D. Seitz, C. Webber, and P.A. Groome

➔ **Ahead of Print Articles and Editorials**

[NPub.org/aheadofprint](https://www.neurology.org/aheadofprint)

- 148 **Risk of Stroke in Cancer Survivors: A Meta-analysis of Population-Based Cohort Studies**
F. Zhang, K. Wang, P. Du, W. Yang, Y. He, T. Li, and Z. Mei
➔ Editorial, p. 143
- 149 **Cerebral Small Vessel Disease MRI Features Do Not Improve the Prediction of Stroke Outcome**
J. Coutureau, J. Asselineau, P. Perez, G. Kuchcinski, S. Sagnier, P. Renou, F. Munsch, R. Lopes, H. Henon, R. Bordet, V. Dousset, I. Sibon, and T. Tourdias
- 150 **Cerebrovascular Disease Progression in Patients With ACTA2 Arg179 Pathogenic Variants**
A. Lauer, S.L. Speroni, J.B. Patel, E. Regalado, M. Choi, E. Smith, J. Kalpathy-Kramer, P. Caruso, D.M. Milewicz, and P.L. Musolino
- 151 **Machine Learning to Predict Delayed Cerebral Ischemia and Outcomes in Subarachnoid Hemorrhage**
J.P.J. Savarraj, G.W. Hergenroeder, L. Zhu, T. Chang, S. Park, M. Meghiani, F.S. Vahidy, Z. Zhao, R.S. Kitagawa, and H.A. Choi
- 152 **Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort**
A.G. Shaikh, S.B. Beylergil, L. Scorr, G. Kilic-Berkmen, A. Freeman, C. Klein, J. Junker, S. Loens, N. Brüggemann, A. Münchau, T. Bäumer, M. Vidailhet, E. Roze, C. Bonnet, J. Jankovic, J. Jimenez-Shahed, N. Patel, L. Marsh, C. Comella, R.L. Barbano, B.D. Berman, I. Malaty, A. Wagle Shukla, S.G. Reich, M.S. Ledoux, A. Berardelli, G. Ferrazzano, N. Stover, W. Ondo, S. Pirio Richardson, R. Saunders-Pullman, Z. Mari, P. Agarwal, C. Adler, S. Chouinard, S.H. Fox, A. Brashear, D. Truong, O. Suchowersky, S. Frank, S. Factor, J. Perlmutter, and H.A. Jinnah
➔ [CME Course](#)
- 153 **A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City**
J.A. Frontera, S. Sabadia, R. Lalchan, T. Fang, B. Flusty, P. Millar-Vernetti, T. Snyder, S. Berger, D. Yang, A. Granger, N. Morgan, P. Patel, J. Gutman, K. Melmed, S. Agarwal, M. Bokhari, A. Andino, E. Valdes, M. Omari, A. Kvernland, K. Lillemoe, S.H.-Y. Chou, M. McNett, R. Helbok, S. Mainali, E.L. Fink, C. Robertson, M. Schober, J.I. Suarez, W. Ziai, D. Menon, D. Friedman, D. Friedman, M. Holmes, J. Huang, S. Thawani, J. Howard, N. Abou-Fayssal, P. Krieger, A. Lewis, A.S. Lord, T. Zhou, D.E. Kahn, B.M. Czeisler, J. Torres, S. Yaghi, K. Ishida, E. Scher, A. de Havenon, D. Placantonakis, M. Liu, T. Wisniewski, A.B. Troxel, L. Balcer, and S. Galetta
➔ [CME Course](#) ➔ [Podcast](#) ➔ [Patient Page](#)
- 154 **Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study**
F. Trucco, D. Ridout, M. Scoto, G. Coratti, M.L. Main, R. Muni Lofra, A.G. Mayhew, J. Montes, M. Pane, V. Sansone, E. Albamonte, A. D'Amico, E. Bertini, S. Messina, C. Bruno, D. Parasuraman, A.-M. Childs, V. Gowda, T. Willis, M. Ong, C. Marini-Bettolo, D.C. De Vivo, B.T. Darras, J. Day, E.A. Kichula, O.H. Mayer, A.A. Navas Nazario, R.S. Finkel, E. Mercuri, and F. Muntoni, on behalf of the International SMA Consortium (iSMAC)
[Open Access Article](#)

Continued

155 **Mutational Analysis of Known ALS Genes in an Italian Population-Based Cohort**

M. Grassano, A. Calvo, C. Moglia, M. Brunetti, M. Barberis, L. Sbaiz, A. Canosa, U. Manera, R. Vasta, L. Corrado, S. D'Alfonso, L. Mazzini, S.W. Scholz, C. Dalgard, J. Ding, R.J. Gibbs, R. Chia, B.J. Traynor, and A. Chiò, The American Genomic Center

156 **Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension**

R. Mantegazza, G.I. Wolfe, S. Muppidi, H. Wiendl, K.P. Fujita, F.L. O'Brien, H.D.E. Booth, and J.F. Howard, on behalf of the REGAIN Study Group

[Open Access Article](#) [Class of Evidence](#)

157 **Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation**

M.E. Farrell, S. Jiang, A.P. Schultz, M.J. Properzi, J.C. Price, J.A. Becker, H.I.L. Jacobs, B.J. Hanseeuw, D.M. Rentz, V.L. Villemagne, K.V. Papp, E.C. Mormino, R.A. Betensky, K.A. Johnson, R.A. Sperling, and R.F. Buckley, on behalf of the Alzheimer's Disease Neuroimaging Initiative and the Harvard Aging Brain Study

[Class of Evidence](#)

158 **Paraneoplastic Myeloneuropathies: Clinical, Oncologic, and Serologic Accompaniments**

S. Shah, R. Vazquez Do Campo, N. Kumar, A. McKeon, E.P. Flanagan, C. Klein, S.J. Pittock, and D. Dubey

[Open Access Article](#)

What's Happening

159 **What's Happening in *Neurology*[®] Clinical Practice**

160 **What's Happening in *Neurology*[®] Neuroimmunology & Neuroinflammation**

161 **What's Happening in Without Borders**

Views & Reviews

162 **Sex Differences in Response to Triptans: A Systematic Review and Meta-analysis**

D.S. van Casteren, T. Kurth, A.H.J. Danser, G.M. Terwindt, and A. MaassenVanDenBrink

Clinical/Scientific Notes

171 **Increased Large Vessel Occlusive Strokes After the Christchurch March 15, 2019, Terror Attack**

T.Y. Wu, D. Myall, D. Palmer, J. Beharry, J.Y. Lim, D.F. Mason, J. Reimers, R. Duncan, J. Weaver, W. Collicutt, P. Mouthaan, A. Lim, M.A. Hurrell, P.A. Barber, A. Ranta, J.N. Fink, and C. Le Heron

NeuroImages

175 **Nelarabine-Induced Myelotoxicity**

A.A. Madhavan, C.M. Carr, H. Alkhateeb, N.P. Staff, and E. Naddaf

Resident & Fellow Section

177 **Resident & Fellow Rounds**

R.E. Strowd III and W. Aamodt

180 **Clinical Reasoning: A 71-Year-Old Man Presenting With Acute Onset Dysarthria and Dysphagia**

G. Spagni, L. Tricoli, A. Modoni, M. Monforte, G. Della Marca, and V. Brunetti

e640 **Pearls & Oysters: A Novel Presentation of Ataxia With Vitamin E Deficiency Caused by *TTPA* Gene Mutation**

A. Zea Vera, W. Liu, C. Thomas, and D.L. Gilbert

[Video](#)

e643 **Teaching NeuroImages: Spinal Neurosarcoidosis: An Eccentric Manifestation**

D. French, F.A. Nascimento, Y. Xu, and S.R. Dunham

e645 **Teaching NeuroImages: SARS-CoV-2–Related Encephalitis: MRI Pattern of Olfactory Tract Involvement**

O. Casez, G. Willaume, S. Grand, B. Nemoz, J. Lupo, P. Kahane, and J.-P. Brion

Patient Page

e647 **The Impact of COVID-19 on Developing Neurologic Disorders**

P. Tekiela and J.J. Majersik

Disputes & Debates: Editors' Choice

185 **Editors' Note: Clinical Significance of Anti-NMDAR Concurrent With Glial or Neuronal Surface Antibodies**

A. Lewis and S. Galetta

185 **Reader Response: Clinical Significance of Anti-NMDAR Concurrent With Glial or Neuronal Surface Antibodies**

E. Lancaster

186 **Reader Response: Clinical Significance of Anti-NMDAR Concurrent With Glial or Neuronal Surface Antibodies**

A. McKeon, D. Dubey, E.P. Flanagan, S.J. Pittock, and A. Zekeridou

188 **Author Response: Clinical Significance of Anti-NMDAR Concurrent With Glial or Neuronal Surface Antibodies**

J. Dalmau and E. Martinez-Hernandez

Department

In the Next Issue of *Neurology*[®]

Neurology®

96 (4)
Neurology 2021;96:e643-189

This information is current as of January 1, 2021

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/96/4.full
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

